Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Pharmacology

Rifampin Concentrations in Various Compartments of the Human Brain: A Novel Method for Determining Drug Levels in the Cerebral Extracellular Space

Thomas Mindermann, Werner Zimmerli, Otmar Gratzl
Thomas Mindermann
Neurological Surgeryand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Werner Zimmerli
Infectious Diseases, University Hospitals Basel, 4031 Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Otmar Gratzl
Neurological Surgeryand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.42.10.2626
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Antimicrobial therapy for brain infections is notoriously difficult because of the limited extent of knowledge about drug penetration into the brain. Therefore, we determined the penetration of rifampin into various compartments of the human brain, including the cerebral extracellular space (CES). Patients undergoing craniotomy for resection of primary brain tumors were given a standard dose of 600 mg of rifampin intravenously before the operation. A microdialysis probe (10 by 0.5 mm) was inserted into the cortex distantly from the resection and was perfused with two different rifampin solutions. Rifampin concentrations in the CES were calculated by the no-net-flux method. Intraoperatively, samples were taken from brain tumor tissue, perifocal tissue, and normal brain tissue in the case of pole resections. Rifampin concentrations in the various samples were determined by using a bioassay with Sarcinea lutea. In the various compartments, rifampin concentrations were highest within tumors (1.37 ± 1.34 μg/ml; n = 8), followed by the perifocal region (0.62 ± 0.67 μg/ml; n = 8), the CES (0.32 ± 0.11 μg/ml; n = 6), and normal brain tissue (0.29 ± 0.15 μg/ml; n = 7). Rifampin concentrations in brain tumors do not adequately reflect concentrations in normal brain tissue or in the CES. Rifampin concentrations in the CES, as determined by microdialysis, are the most reproducible, and the least scattered, of the values for all compartments evaluated. Rifampin concentrations in all compartments exceed the MIC for staphylococci and streptococci. However, CES concentrations may be below the MICs for some mycobacterial strains.

Dose recommendations for antibiotic treatment of bacterial infections of the brain are usually based on concentrations in cerebrospinal fluid (CSF). Alternatively, drug levels in brain tumors, rather than those in nontumorous brain tissue or the cerebral extracellular space (CES), are taken into consideration.

Rifampin is used for its bactericidal effect on mycobacteria and its excellent antistaphylococcal effect (16). Penetration of antibiotics into the central nervous system (CNS) has been determined only in the tissue of brain tumors, the CSF, and intracranial abscess formations (1, 2, 4, 13). In contrast to other antistaphylococcal drugs, rifampin penetrates well into the CSF (1, 13), and consequently it is used in the treatment of CSF shunt infections (7). Therefore, rifampin would be a good candidate for the treatment of staphylococcal or streptococcal brain abscesses and of infections after neurosurgery. However, there are no data on its penetration into nontumorous brain tissue or into other compartments of the brain, except from animal experiments (11).

Since brain infections spread mainly through the CES, we determined rifampin concentrations in the CES in comparison with those in other brain compartments. We examined tissue samples and used intraoperative microdialysis in patients undergoing craniotomy for tumor removal. The tissue samples were taken from the following sites: nontumorous brain tissue distant from a brain tumor, perifocal tissue in close proximity to a brain tumor, and brain tumor tissue. Rifampin concentrations in the CES were determined by using intraoperative microdialysis.

(This work was presented in part at the 65th Annual Meeting of the American Association of Neurological Surgeons, Denver, Colo., April 1997.)

MATERIALS AND METHODS

Patients.This prospective, open trial was started in February 1996. The study was approved by the Ethical Committee of the University Hospitals of Basel. Patients who were admitted to the Department of Neurosurgery for surgery of a primary brain tumor, and who had no previous antibiotic therapy within 5 days prior to surgery, were eligible for the trial provided that the expected duration of the operation exceeded 3 h. All patients gave written informed consent to participation in the trial. Each patient entering the trial received a single preoperative dose of 600 mg of rifampin infused over 3 h in 500 ml of physiological saline, starting 3 h before skin incision. No further antibiotics were administered.

Microdialysis.Prior to the insertion of the microdialysis probe into the brain and the commencement of microdialysis, the entire tubing and the probe of the microdialysis system were flushed with the rifampin solution of the perfusate, thus eliminating the problem of rifampin loss due to its adherence to plastic surfaces. After craniotomy and opening of the dura, the microdialysis probe (membrane length, 10 mm; membrane diameter, 0.5 mm) was introduced into the brain parenchyma distantly from the resection. We used CMA/20 microdialysis probes (molecular size cutoff, 20,000 Da; molecular size of rifampin, 823 Da), a CMA/102 perfusor, and a CMA/142 collector (Microdialysis AB, Stockholm, Sweden). The probe was then perfused with two solutions of different rifampin concentrations (0.25 and 0.5 μg/ml in the first two patients and 0.5 and 1.0 μg/ml in the following six patients) for 1 h each at a rate of 3 μl/min, resulting in 180 μl for each dialysate. As described in our animal study (11), rifampin concentrations in the CES were determined by calculating the loss or gain of rifampin in the two solutions, using the no-net-flux method (also called the equilibrium method, or the Lönnroth method) (6). The resulting rifampin concentrations in the CES represent the average concentration in the CES over a period of 2 h. For the calculation of the rifampin concentrations in the CES, the actual rifampin concentrations in the perfusates were determined, since rifampin solutions were stored in plastic vials before the commencement of the experiments. Due to the well-known adherence of rifampin to plastic surfaces, these determinations are indeed crucial in order to obtain accurate results. We found a 60.5% ± 14% (n = 8) reduction with the 0.5-μg/ml perfusates and a 54.8% ± 18% (n = 6) reduction with the 1.0-μg/ml perfusates.

Tissue samples.Intraoperatively, tissue samples were taken from unaffected brain tissue which was resected with pole resections, from perifocal tissue surrounding the tumor, and from tumor tissue. At the same time, 5 ml of peripheral venous blood was drawn from the patient in order to determine concentrations of rifampin in serum. Brain tissue samples were briefly and gently rinsed with 0.9% saline until they appeared macroscopically free of contaminating blood. The gently rinsed brain tissue was homogenized with a Teflon homogenizer in 0.9% saline (1:1 [wt/vol]) before the determination in the bioassay. Tissue concentrations were calculated by multiplying the concentration in the homogenate by 2.

Bioassay and standard solutions.The rifampin concentrations of all samples were determined by an agar diffusion bioassay usingSarcina lutea as the test strain, as previously described (11, 17). In addition, the perfusates’ concentrations, which were used for calculation, were determined by the same bioassay. This was realized to be important for accurate results because of a considerable loss of rifampin at plastic surfaces. Standard solutions were prepared from a commercially available intravenous preparation of rifampin by diluting stock solutions with pooled serum, resulting in a final concentration in serum of 50%. Identical standard curves were obtained with standards prepared in 0.9% saline or 50% serum, respectively. Therefore, all specimens (rifampin perfusate, serum, CES dialysates, and tissue homogenates) were assayed on the same plate with the same 50% serum standards. The bioassay has a detection limit of 0.05 μg/ml and does not differentiate between rifampin and its metabolites. The agar diffusion assay has an excellent correlation (r = 0.988) with high-pressure liquid chromatography (18). Since this assay does not differentiate between rifampin and its metabolites, the total antimicrobial activity is determined, which is adequate for the question under investigation. The reproducibility of our assay was good, with an intraassay coefficient of variation of 2.3% and an interday coefficient of variation of 4.4%.

Statistical methods.Data are reported as means ± standard deviation. For multiple comparisons we performed the analysis-of-variance test.

RESULTS

From February 1996 until July 1997, eight patients fulfilled the study criteria and were evaluated. Patient characteristics are listed in Table 1. None of the eight patients had any side effects of the study drug, and no intraoperative or postoperative complications occurred. Rifampin concentrations in the various compartments are listed in Table2. Serum samples and whole tissue samples were taken beginning 77 ± 43 min after the infusion of rifampin was completed. Sampling of sera and tissues was performed within a period of 23 ± 15 min. Microdialysis was started 67 ± 28 min after the infusion of rifampin was completed in seven patients and 44 min before the completion of the infusion in one patient (patient 6). Microdialysis samples were obtained within a 125-min time period for all patients. Rifampin concentrations in tissue samples from brain tumors were higher than in tissue samples from normal brain tissue or the CES. A typical example of the determination of rifampin concentrations in the CES according to the no-net-flux method is shown in Fig. 1. For the first two patients, the CES values could not be calculated because the actual rifampin concentrations in the perfusates were not determined. For these two patients (patients 1 and 2), we determined the rifampin concentrations in the serum and tissue samples only (Table 2). For patient 3, the rifampin concentration in normal brain tissue could not be determined because no pole resection was performed (Table 1). The differences in rifampin concentrations in the various CNS compartments did not gain statistical significance due to the high variability of the levels of rifampin in the tissue samples.

View this table:
  • View inline
  • View popup
Table 1.

Patient characteristics

View this table:
  • View inline
  • View popup
Table 2.

Rifampin concentrations in the various compartments

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Rifampin in the CES of patient 6. The determination of the concentration of rifampin in the CES in one patient illustrates the principle of the no-net-flux method. The probe was first perfused with a 0.5-μg/ml solution of rifampin at a constant flow rate of 3 μl/min, resulting in 180 μl of dialysate after 1 h. It was then perfused with a 1.0-μg/ml solution of rifampin under the same conditions. The concentrations of rifampin in the perfusates and the dialysates were determined together with those in the other samples and were used for calculation. The concentration of rifampin in the CES was calculated from the perfusates’ loss or gain in rifampin. The intercept with the zero line indicates equilibrium, i.e., equal concentrations inside and outside the microdialysis probe. At this intercept, the concentration of rifampin in the CES (0.24 μg/ml) was determined from the x axis. This represents the average concentration of rifampin in the CES over a period of 2 h.

DISCUSSION

This study is unique because it is the first in which actual drug concentrations were measured in the CES in humans. Microdialysis allows for direct in vivo measurement of drug concentrations in the CES. Interstitial drug concentrations are relevant in antibacterial treatment, since bacteria mainly spread through the extracellular space. Until now, skin blisters were the most common model for measurement of drug concentrations in interstitial fluids (19). Recently, microdialysis and microvoltametry have been used to determine concentrations of antibiotics in the CES (3, 8-11). As a method, microvoltametry has the disadvantage that it cannot distinguish between bound and unbound drug. It has the advantage of high temporal resolution. Microdialysis measures unbound drug only, but it has the disadvantage of a worse temporal resolution. In our model, one concentration point of rifampin in the CES represents the average drug concentration during a 2-h period.

Our data show a clear trend in the penetration of rifampin into the various compartments of the human brain. Apart from values in serum, the highest rifampin concentrations were found in the tissue of primary brain tumors, followed by perifocal tissue, CES, and normal brain tissue. Interestingly, concentrations of rifampin in the CES were in the same range as those in samples of normal brain tissue. Both compartments had almost fivefold-lower rifampin concentrations than tumors. Furthermore, the variability of levels of rifampin in tumor and perifocal tissues is high, probably due to the highly variable impairment of the blood-brain barrier. This indicates that the standard method for determining levels of drugs in brain tissues by measuring their concentrations in tissue samples from brain tumors yields nonreproducible results and, in the case of rifampin, overestimates its penetration into normal brain tissue or the CES by a factor of 4 to 5. This overestimation may be especially important in the late treatment course, when the blood-brain barrier is restored.

Anatomically and functionally, the blood-brain barrier differs from the blood-CSF barrier (14). In the case of rifampin, this functional difference becomes obvious, since rifampin penetrates into the CSF at a rate about 10-fold that for the CES (13). Similar discrepancies between the blood-brain barrier and the blood-CSF barrier have been observed for fusidic acid (12) and clindamycin (15).

Our data lend theoretical support to the clinically observed effectiveness of rifampin in the treatment of cerebral staphylococcal and streptococcal infections. Rifampin penetrates into the CES following a standard dose of 600 mg given intravenously, reaching concentrations exceeding those necessary for the treatment of staphylococcal and streptococcal infections. Yet CES concentrations may be below MICs for some mycobacterial strains, indicating why the treatment of brain tuberculoma with a standard dosage of antimycobacterial drugs may fail (5).

This new method for determining the levels of drugs in the CES provides information on their penetration into the interstitial space of the CNS or any other organ in vivo. In the case of rifampin, microdialysis provides data which are significantly less scattered, and therefore more reproducible, than data derived from whole-tissue samples from a variety of CNS compartments. This method should be suitable for measurements of other drugs in the CES, such as other antibiotics, anticonvulsants, or psychotropic drugs.

ACKNOWLEDGMENTS

This work was supported by a grant (to T.M.) from “Oberärzte-Pool Chirurgie,” University Hospitals Basel, Basel, Switzerland.

We thank Helen Langemann for help with the intraoperative microdialysis and Zarko Rajacic for performing the bioassays.

FOOTNOTES

    • Received 6 October 1997.
    • Returned for modification 22 March 1998.
    • Accepted 8 June 1998.
  • Copyright © 1998 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Conforti P.,
    2. Cambria S.,
    3. Magaudda P. L.,
    4. Pennisi L.
    Diffusione antibiotica nei tessuti del sistema nervoso centrale. Minerva Neurochir. 15 1971 192 200
    OpenUrlPubMed
  2. 2.↵
    1. DeLouvois J.,
    2. Gortvai P.,
    3. Hurley R.
    Antibiotic treatment of abscesses of the central nervous system. Br. Med. J. 2 1977 985 987
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Granero L.,
    2. Santiago M.,
    3. Cano J.,
    4. Machado A.,
    5. Peris J. E.
    Analysis of ceftriaxone and ceftazidime distribution in cerebrospinal fluid of and cerebral extracellular space in awake rats by in vivo microdialysis. Antimicrob. Agents Chemother. 39 1995 2728 2731
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Kaplan K.
    Brain abscess. Med. Clin. North Am. 69 1985 345 360
    OpenUrlPubMedWeb of Science
  5. 5.↵
    1. Lees A. J.,
    2. MacLeod A. F.,
    3. Marshall J.
    Cerebral tuberculomas developing during treatment of tuberculous meningitis. Lancet i 1980 1208 1211
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Lönnroth P.,
    2. Jansson P. A.,
    3. Smith U.
    A microdialysis method allowing characterization of intracellular water space in humans. Am. J. Physiol. 253 1987 E228 E231
    OpenUrlPubMedWeb of Science
  7. 7.↵
    1. McLaurin R. L.,
    2. Frame P. T.
    Treatment of infections of cerebrospinal fluid shunts. Rev. Infect. Dis. 9 1987 595 603
    OpenUrlPubMed
  8. 8.↵
    1. Meulemans A.,
    2. Henzel D.,
    3. Brun-Pacaud M.,
    4. Mohler J.,
    5. Vicart P.,
    6. Tran Ba Huy P.
    On-line pharmacokinetics of chloramphenicol in rat cortex by in vivo electrochemical detection. Chemotherapy (Basel) 30 1984 353 357
    OpenUrl
  9. 9.↵
    1. Meulemans A.,
    2. Vicart P.,
    3. Henzel D.,
    4. Mohler J.,
    5. Vulpillat M.
    Cefsulodin penetration into rat brain: extracellular versus total concentration. Chemotherapy (Basel) 32 1986 393 398
    OpenUrl
  10. 10.↵
    1. Meulemans A.,
    2. Vicart P.,
    3. Mohler J.,
    4. Henzel D.,
    5. Vulpillat M.
    Permeability of nitroimidazoles in rat cortex. Chemotherapy (Basel) 32 1986 486 493
    OpenUrl
  11. 11.↵
    1. Mindermann T.,
    2. Landolt H.,
    3. Zimmerli W.,
    4. Rajacic Z.,
    5. Gratzl O.
    Penetration of rifampicin into the brain tissue and cerebral extracellular space of rats. J. Antimicrob. Chemother. 31 1993 731 737
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Mindermann T.,
    2. Zimmerli W.,
    3. Rajacic Z.,
    4. Gratzl O.
    Penetration of fusidic acid into human brain tissue and cerebrospinal fluid. Acta Neurochir. 121 1993 12 14
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Nau R.,
    2. Prange H. W.,
    3. Menck S.,
    4. Kolenda H.,
    5. Visser K.,
    6. Seydel J. K.
    Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J. Antimicrob. Chemother. 29 1992 719 724
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Pardridge W. M.
    Drug delivery to the brain. J. Cereb. Blood Flow Metab. 17 1997 713 731
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Picardi J. L.,
    2. Lewis H. P.,
    3. Tan J. S.,
    4. Phair J. P.
    Clindamycin concentrations in the central nervous system of primates before and after head trauma. J. Neurosurg. 43 1975 717 720
    OpenUrlPubMed
  16. 16.↵
    1. Thornsberry C.,
    2. Hill B. C.,
    3. Swenson J. M.,
    4. McDougal L. K.
    Rifampin: spectrum of antibacterial activity. Rev. Infect. Dis. 5 1983 S412 S417
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Tshefu K.,
    2. Zimmerli W.,
    3. Waldvogel F. A.
    Short-term administration of rifampicin in the prevention or eradication of infection due to foreign bodies. Rev. Infect. Dis. 5 1983 S474 S480
    OpenUrlPubMedWeb of Science
  18. 18.↵
    1. Weber A.,
    2. Opheim K. E.,
    3. Smith A. L.,
    4. Wong K.
    High-pressure liquid chromatographic quantitation of rifampin and its two major metabolites in urine and serum. Rev. Infect. Dis. 5 1983 S433 S439
    OpenUrl
  19. 19.↵
    1. Zimmerli W.,
    2. Sansano S.,
    3. Wittke B.
    Pharmacokinetics of cefetamet in plasma and skin blister fluid. Antimicrob. Agents Chemother. 40 1996 102 104
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Rifampin Concentrations in Various Compartments of the Human Brain: A Novel Method for Determining Drug Levels in the Cerebral Extracellular Space
Thomas Mindermann, Werner Zimmerli, Otmar Gratzl
Antimicrobial Agents and Chemotherapy Oct 1998, 42 (10) 2626-2629; DOI: 10.1128/AAC.42.10.2626

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Rifampin Concentrations in Various Compartments of the Human Brain: A Novel Method for Determining Drug Levels in the Cerebral Extracellular Space
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Rifampin Concentrations in Various Compartments of the Human Brain: A Novel Method for Determining Drug Levels in the Cerebral Extracellular Space
Thomas Mindermann, Werner Zimmerli, Otmar Gratzl
Antimicrobial Agents and Chemotherapy Oct 1998, 42 (10) 2626-2629; DOI: 10.1128/AAC.42.10.2626
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Antibiotics, Antitubercular
brain
Extracellular Space
rifampin

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596